FR15C0073I2 - Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) - Google Patents

Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Info

Publication number
FR15C0073I2
FR15C0073I2 FR15C0073C FR15C0073C FR15C0073I2 FR 15C0073 I2 FR15C0073 I2 FR 15C0073I2 FR 15C0073 C FR15C0073 C FR 15C0073C FR 15C0073 C FR15C0073 C FR 15C0073C FR 15C0073 I2 FR15C0073 I2 FR 15C0073I2
Authority
FR
France
Prior art keywords
reverse transcriptase
nucleoside reverse
transcriptase inhibitor
nnrti
nrti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0073C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0073(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR15C0073I1 publication Critical patent/FR15C0073I1/fr
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Application granted granted Critical
Publication of FR15C0073I2 publication Critical patent/FR15C0073I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR15C0073C 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) Active FR15C0073I2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number Publication Date
FR15C0073I1 FR15C0073I1 (enExample) 2015-04-12
FR15C0073I2 true FR15C0073I2 (fr) 2016-02-12

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
FR15C0073C Active FR15C0073I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1022C Active FR16C1022I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1024C Active FR16C1024I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Family Applications After (4)

Application Number Title Priority Date Filing Date
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1022C Active FR16C1022I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1024C Active FR16C1024I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015040I1 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0073I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500053I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I2 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
HRP20050104B1 (hr) 2002-08-09 2014-02-14 Janssen Pharmaceutica N.V. Postupci za pripremu 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
KR100860136B1 (ko) 2003-01-14 2008-09-25 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
WO2006024668A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
KR101276571B1 (ko) * 2004-09-02 2013-06-18 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
DK1789139T3 (da) * 2004-09-02 2012-07-09 Janssen Pharmaceutica Nv Fumarat af 4-((4-((4-(2-cyanethenyl)-2,6-dimethylphenylamino-2-pyrimidinylaminobenzonitril
UA92469C2 (en) * 2004-09-02 2010-11-10 Янссен Фармацевтика Н.В. Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl amino benzonitrile
EP1632232B3 (en) * 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
SI2051703T1 (sl) * 2005-12-14 2011-01-31 Cipla Ltd Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike
PL1981506T6 (pl) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
WO2009115652A2 (fr) * 2008-01-03 2009-09-24 Universite De La Mediterannee, Aix-Marseille Ii Composition et procedes utilisables lors d'un traitement anti-vih
CN102711834B (zh) * 2008-12-24 2015-08-26 爱尔兰詹森科学公司 治疗hiv的可植入装置
ES2600878T3 (es) 2009-12-21 2017-02-13 Janssen Sciences Ireland Uc Implante removible, degradable, para la liberación prolongada de un compuesto activo
DK2932970T3 (en) 2010-01-27 2018-05-28 Viiv Healthcare Co ANTIVIRAL THERAPY
MX347512B (es) * 2010-11-19 2017-04-28 Gilead Sciences Inc Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir.
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
ES2680146T3 (es) * 2011-09-16 2018-09-04 Hetero Research Foundation Hidrocloruro de rilpivirina
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
SI3346995T1 (sl) 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
ES2970870T3 (es) 2016-10-24 2024-05-31 Janssen Sciences Ireland Unlimited Co Composiciones dispersables
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
BR112019021918A2 (pt) * 2017-04-18 2020-05-26 Cipla Limited Terapia de combinação para uso no tratamento de infecções retroviriais
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
CA3152105A1 (en) 2019-11-29 2021-06-03 Wai Yip Thomas Lee Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
ES2093106T3 (es) 1990-07-19 1996-12-16 Otsuka Pharma Co Ltd Preparacion solida.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
JPH07503943A (ja) * 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
AU4079593A (en) 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
EP1214059B1 (en) 1999-09-21 2005-05-25 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
CA2404687A1 (en) 2000-03-30 2001-10-11 Nemichand B. Jain Sustained release beadlets containing stavudine
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
AU2002221096A1 (en) 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions improved in solublity in water
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
JO3429B1 (ar) † 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
HRP20050104B1 (hr) 2002-08-09 2014-02-14 Janssen Pharmaceutica N.V. Postupci za pripremu 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
JP2006508134A (ja) 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
AP1927A (en) 2002-11-15 2008-12-10 Tibotec Pharm Ltd Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2004210081B2 (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica N.V. Pyrimidine derivatives for the prevention of HIV infection
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
SG153800A1 (en) 2004-06-08 2009-07-29 Vertex Pharma Pharmaceutical compositions
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1632232B3 (en) 2004-09-02 2022-03-30 Janssen Pharmaceutica NV Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
CA2587710C (en) 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
CA2603851A1 (en) * 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior Unversity Multi-layer structure having a predetermined layer pattern including an agent
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
JP5243247B2 (ja) 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
PL1981506T6 (pl) 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
UY30431A1 (es) 2006-06-23 2008-01-31 Tibotec Pharm Ltd Suspensiones acuosas de tmc278
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
DK2175857T3 (da) 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
CY2015038I2 (el) 2016-08-31
NO2016026I1 (no) 2016-12-20
US20180228800A1 (en) 2018-08-16
CY2015039I1 (el) 2016-08-31
HRP20150798T4 (hr) 2023-06-09
NL300768I1 (enExample) 2015-12-16
US20100029591A1 (en) 2010-02-04
NL300781I1 (enExample) 2016-04-19
HUS1500054I1 (hu) 2016-03-29
AP2006003551A0 (en) 2006-04-30
NO2014031I1 (no) 2015-01-05
JP2007520443A (ja) 2007-07-26
NO2014032I1 (no) 2015-01-05
US20220008417A1 (en) 2022-01-13
CY2015040I2 (el) 2016-08-31
JP2012051915A (ja) 2012-03-15
AU2011201123A1 (en) 2011-04-07
EP1663240B2 (en) 2023-03-01
NO2014030I2 (no) 2014-12-18
CY2016049I1 (el) 2017-07-12
CY2015040I1 (el) 2016-08-31
BE2015C053I2 (enExample) 2023-12-14
US20150283135A1 (en) 2015-10-08
MXPA06002437A (es) 2006-06-20
CY2016049I2 (el) 2017-07-12
AP2109A (en) 2010-02-26
AU2004268390B2 (en) 2011-03-31
JP5820045B2 (ja) 2015-11-24
FR16C1024I1 (fr) 2017-02-03
JP2015044839A (ja) 2015-03-12
AU2019200813A1 (en) 2019-02-28
AU2016210733B2 (en) 2018-11-08
PL1663240T3 (pl) 2015-10-30
US20140349971A1 (en) 2014-11-27
AU2014203484B2 (en) 2016-09-29
LU92853I2 (fr) 2015-12-21
FI1663240T4 (fi) 2023-04-25
HUS1500052I1 (hu) 2016-03-29
US8841310B2 (en) 2014-09-23
CY2015039I2 (el) 2016-08-31
HUS1600059I1 (hu) 2017-02-28
NO2014031I2 (no) 2014-12-18
AU2004268390A1 (en) 2005-03-10
US20190216807A1 (en) 2019-07-18
EP1663240A1 (en) 2006-06-07
IL213104A0 (en) 2011-07-31
US20170100398A1 (en) 2017-04-13
CA2537095A1 (en) 2005-03-10
PL1663240T5 (pl) 2024-02-26
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
NO2016025I1 (enExample) 2016-12-20
FR16C1022I1 (fr) 2017-02-03
AU2011201123B2 (en) 2013-10-10
FR15C0073I1 (enExample) 2015-04-12
CN101060844A (zh) 2007-10-24
KR20060090658A (ko) 2006-08-14
US20200171027A1 (en) 2020-06-04
HRP20150798T1 (hr) 2015-09-11
LU92854I2 (fr) 2015-12-21
FR15C0072I1 (enExample) 2015-04-12
FR15C0071I1 (enExample) 2015-04-12
NO2014032I2 (no) 2014-12-18
NO2014030I1 (no) 2015-01-05
FR15C0072I2 (fr) 2019-05-17
WO2005021001A1 (en) 2005-03-10
IL173438A0 (en) 2006-06-11
CY2016048I2 (el) 2017-07-12
AU2016210733A1 (en) 2016-08-25
LU92855I2 (fr) 2015-12-21
MY169670A (en) 2019-05-08
NO20061374L (no) 2006-03-27
CY2016048I1 (el) 2017-07-12
LTPA2016044I1 (lt) 2017-01-10
HK1092698A1 (en) 2007-02-16
NL300768I2 (nl) 2023-08-09
FR15C0071I2 (fr) 2016-02-12
CA2537095C (en) 2012-05-29
HUS1500053I1 (hu) 2016-03-29
CY2015038I1 (el) 2016-08-31
IL213104A (en) 2016-02-29
JP5507791B2 (ja) 2014-05-28
IL173438A (en) 2012-03-29
CN101060844B (zh) 2012-01-04
LTC1663240I2 (lt) 2022-05-25
LTPA2016045I1 (lt) 2017-01-10
NZ545306A (en) 2009-11-27
HUS1600058I1 (hu) 2017-02-28
EP1663240B1 (en) 2015-04-22
AU2014203484A1 (en) 2014-07-17
NO334877B1 (no) 2014-06-23

Similar Documents

Publication Publication Date Title
FR15C0072I2 (fr) Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
DZ3420A1 (fr) Combinaison d'herbicides avec des sulfonylurees speciales
ATE370124T1 (de) Inhibitoren dernicht-nukleosid-inhibitoren der reversen transkriptase
LTPA2016046I1 (lt) Modifikuoti fluorintų nukleozidų analogai
MA28695B1 (fr) Derives pyrimidines uree en tant qu'inhibiteurs de kinase
EP1758453A4 (en) C-PURIN NUCLEOSIDE ANALOGUE AS AN INHIBITOR OF THE RNA-DEPENDENT VIRAL RNA POLYMERASE
FR12C0035I2 (fr) Derives de pyrimidines inhibiteurs de vih
NO20031852D0 (no) Pyrimidin-2,4,6-trion metalloproteinase inhibitorer
DK1687257T3 (da) Aminosubstituerede ethylaminoagonister af den beta2-adrenerge receptor
ITMI20031847A1 (it) Composizione di fluoropolimeri espandibili senza l'impiego di agenti espandenti.
DE60324418D1 (de) Nicht-nukleosidische inhibitoren der reversen transkriptase
EP1901621A4 (en) BEVERAGE WITH A COMBINATION OF FISH OIL AND PROBIOTICS
BRPI0516242A (pt) compostos tieno-pirimidina tendo atividade fungicida
EE200200690A (et) Mittenukleosiidsed pöördtranskriptaasi inhibiitorid
PL364414A1 (en) Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors
EP1583530A4 (en) 2-AMINOTHIAZOLE ALLOSTERIC AMPLIFIERS OF A1 ADENOSINE RECEPTORS
IL160627A0 (en) Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors
EP1326640A4 (en) NON-NUCLEOSIDIC REVERSE-TRANSCRIPTASE INHIBITOR AS ANTIRETROVIRAL THERAPY
TWI365744B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors